Global
vaccine experts and officials from all 26 African «meningitis belt» countries have convened in Addis Ababa, Ethiopia to celebrate one of Africa's biggest public health achievements — the introduction of a
vaccine, MenAfriVac ®, designed, developed, and produced for use in Africa, that in five years of use has nearly eliminated serogroup A
meningococcal disease from meningitis belt countries and is now being integrated into routine national immunization
programs.